NCT02010645 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle. Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle. Eltrombopag: Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle. Decitabine: Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
- id
- FG000
- title
- Eltrombopag + Decitabine
- periods
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 6
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 6
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Overall Study
- recruitment Details
- Recruitment period: March 2014 to February 2015
Complete source fields
- groups
- description
- Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle. Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle. Eltrombopag: Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle. Decitabine: Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
- id
- FG000
- title
- Eltrombopag + Decitabine
- periods
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 6
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 6
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Overall Study
- recruitment Details
- Recruitment period: March 2014 to February 2015
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle